skynesher / iStockphoto.com
Samsung and HP are just two technology companies that have diversified and invested in the life sciences industry. What impact will this type of activity have on the sector and will it be beneficial in the long run? LSIPR finds out.
When you think of big players in the life sciences sector, companies such as Gilead Sciences, Pfizer and AstraZeneca might spring to mind.
But the life sciences arena is changing, and companies that you might think better placed within the technology sector are making their presence felt in, and may be set to disrupt, the industry.
According to a report earlier this year by research and development insight company PatSnap, as of April 26, technology companies Philips and HP are among the top ten most intensive filers of patents covering enabling technologies in the synthetic biology field.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Samsung, HP, big data, patent filings, medical technology, research and development, consumer electronics, personalised medicine, life sciences, monitor
